Human immunodeficiency virus envelope peptide–Major histocompatibility complex class I complex (HIV Env–MHC I)

Human immunodeficiency virus envelope peptide–Major histocompatibility complex class I complexes are molecular assemblies consisting of a peptide fragment derived from the HIV envelope glycoprotein (gp120 or gp41) bound within the groove of an MHC class I molecule [Goulder & Watkins, 2008, Nature Reviews Immunology]. These complexes are expressed on the surface of HIV-infected cells and serve as the primary signal for recognition by CD8+ cytotoxic T lymphocytes (CTLs) via their T-cell receptors (TCRs) [Hale et al., 2017, Molecular Therapy]. In the context of HIV infection, the presentation of these peptides is crucial for the immune system's attempt to identify and eliminate virally infected cells [Walker & McMichael, 2012, Nature Medicine]. However, HIV often evades this response through mutations in the Env protein that prevent peptide binding to MHC or recognition by TCRs [Borrow et al., 1997, Journal of Virology]. Therapeutic strategies targeting these complexes include the development of TCR-mimetic antibodies and chimeric antigen receptor (CAR) T-cells designed to specifically bind the peptide-MHC assembly [Stewart-Jones et al., 2009, Journal of Immunology]. These interventions aim to bypass the limitations of natural TCR recognition and provide a targeted approach to eradicating the viral reservoir [He et al., 2023, Frontiers in Immunology]. By focusing on conserved epitopes, these therapies may overcome the challenge of viral diversity and mutational escape. Furthermore, the specificity of these agents for the peptide-MHC complex minimizes damage to non-infected cells, although cross-reactivity remains a concern.

Other names

HIV Env-HLA-I complexHIV gp120/gp41 peptide-MHC complexpMHC complex (HIV Env)HIV-1 envelope peptide-HLA complex

Therapeutic agents, such as TCR-mimetic antibodies or CAR-T cells, bind specifically to the HIV Env peptide presented within the MHC class I groove, triggering the recruitment and activation of effector immune cells or direct lysis of the HIV-infected cell [Stewart-Jones et al., 2009, Journal of Immunology].